Tris Pharma

85 articles about Tris Pharma

• Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder

  9/25/2023

  Tris Pharma, Inc. today announced that Health Canada has authorized the use of Quillivant ® ER (extended release) for the treatment of attention deficit hyperactivity disorder (ADHD) in children ages 6 to 12.

• Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference

  9/5/2023

  Tris Pharma, Inc. (Tris), today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.

• Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder

  8/28/2023

  Tris Pharma, Inc. announced that the company has been awarded a grant expected to provide up to $16.6M over five years from the National Institute on Drug Abuse, part of the National Institutes of Health.

• Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline

  5/2/2023

  Tris Pharma, Inc. today announced the appointments of Thomas Englese as chief commercial officer and Marc Lesnick, Ph.D., as chief development officer.

• Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone

  12/13/2022

  Tris Pharma, Inc. today announced new clinical data from its oral human abuse potential study in patients who are nondependent recreational opioid users, which demonstrate that cebranopadol (TRN-228) possesses significantly less likeability at high doses, above the therapeutic range versus immediate release (IR) formulations of tramadol or oxycodone.

• Tris Pharma Announces Acquisition of New, Late-Stage Drug Candidate for Pain

  12/7/2022

  Tris Pharma, Inc. today announced that it has acquired rights to TRN-261 a non-opioid drug candidate that Tris intends to develop for multiple indications within acute and chronic pain.

• Tris Pharma and Pediatrix Therapeutics Announce Expansion of Partnership to Commercialize Tris's ADHD Portfolio and Pipeline Products in China

  12/1/2022

  Tris Pharma, Inc. announced today that they have expanded their partnership whereby Pediatrix Therapeutics received exclusive rights to commercialize Tris's entire FDA-approved ADHD portfolio as well as ADHD pipeline products in China.

• Tris Pharma Announces Continued Supply and Availability of DYANAVEL® XR (amphetamine) Tablets and Oral Suspension for ADHD Despite Adderall shortage

  10/19/2022

  Tris Pharma, Inc. (Tris) a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today that DYANAVEL® XR (amphetamine) extended-release tablets, for oral use, CII and DYANAVEL® XR.

• Tris Pharma Announces Availability of New DYANAVEL® XR (amphetamine) Tablets for ADHD

  8/16/2022

  Tris Pharma, Inc.  announced today that DYANAVEL® XR (amphetamine) extended-release tablets, for oral use, CII are now available in pharmacies.

• Tris Pharma Announces Development of a Very Low Sodium and Once-Nightly Oxybate Formulation

  7/27/2022

  Tris Pharma, Inc. ("Tris"), a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today that it has successfully developed an oxybate formulation for the treatment of cataplexy.

• Tris Pharma Announces Publication of Study Results Highlighting the Efficacy and Safety of DYANAVEL® XR (amphetamine) Tablets for the Treatment of the Symptoms of ADHD in Adults

  7/22/2022

  Tris Pharma, Inc. ("Tris"), a fully integrated pharmaceutical company with a robust portfolio of CNS products announced the publication of a Phase 3 study in the Journal of Clinical Psychiatry that demonstrated that adult patients with ADHD who took DYANAVEL XR.

• Tris Pharma announces U.S. Court of Appeals for the Federal Circuit Affirms Validity of Quillivant XR® Patents; Rules Teva Infringes Tris Patents

  7/20/2022

  Tris Pharma, Inc. ("Tris"), a fully integrated pharmaceutical company with a robust portfolio of CNS products announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision on July 7, 2022 upholding the validity and infringement of various patents relating to Quillivant XR ®.

• Tris Pharma Announces FDA Approval of DYANAVEL® XR (amphetamine) Once-Daily Extended-Release Oral Tablets, CII, for ADHD

  11/5/2021

  Tris Pharma, Inc. (Tris) announced today that the U.S. Food and Drug Administration has approved Dyanavel XR (amphetamine) for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

• Tris Pharma® Hires Seasoned Business Development Executive

  10/7/2021

  Tris Pharma, Inc. today announced that Anthony Amato has joined the company as Executive Vice President Business Development – Generics Division. 

• Tris Pharma® Announces Acquisition of Park Therapeutics - Pain Company with First-In-Class, Phase III-Ready New Chemical Entity (NCE)

  4/29/2021

  - Novel mechanism of action, highly differentiated safety profile, 2000+ subjects studied in 27 clinical trials across Europe and US; FDA Fast Track status granted - NCE has potential to addresses significantly under-served market comprising acute and chronic pain, central and peripheral neuropathy, cancer pain, and addiction treatment

• Tris Pharma and Athena Bioscience Announce Exclusive License Agreement to Commercialize Near-to-Market Long-Acting Antihypertensive Product in the U.S.

  2/22/2021

   Tris Pharma, Inc. ("Tris") and Athena Bioscience LLC ("Athena") announced today that they have entered into an agreement by which Athena received exclusive rights to commercialize a long-acting antihypertensive product developed using  Tris' proprietary technology.

• Tris Pharma to Debut Amphetamine Extended-Release Tablet Efficacy and Safety Data at the 2021 APSARD Annual Meeting

  1/15/2021

  Tris Pharma, Inc. announced that it will present pivotal efficacy and safety data on its new amphetamine extended-release tablet at the virtual annual meeting of American Professional Society of ADHD and Related Disorders to be held from Friday, January 15 through Sunday, January 17, 2021.

• Tris Pharma Hires Seasoned Research & Development Executive

  12/18/2020

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder

• Tris Pharma and Neuraxpharm Group Announce Partnership to Commercialize Tris' Quillivant XR and Quillichew ER in Europe

  12/8/2020

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and Neuraxpharm Group ("Neuraxpharm"), a leading European specialty pharma

• Tris Pharma and Medison Pharma Announce Exclusive License Agreement to Commercialize Tris' Quillivant XR in Israel

  11/17/2020

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and Medison Pharma ("Medison"), a leading international commercial partner for highly innovat